Neoleukin Therapeutics, Inc. (NASDAQ:NLTX – Get Free Report) shares were down 4.8% on Monday . The stock traded as low as $21.50 and last traded at $21.83. Approximately 224,694 shares were traded during trading, an increase of 348% from the average daily volume of 50,104 shares. The stock had previously closed at $22.92.
Neoleukin Therapeutics Stock Performance
The stock has a fifty day simple moving average of $14.67 and a two-hundred day simple moving average of $17.59. The stock has a market capitalization of $205.16 million, a price-to-earnings ratio of -7.02 and a beta of 1.11.
Neoleukin Therapeutics Company Profile
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Featured Articles
- Five stocks we like better than Neoleukin Therapeutics
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Palantir Stock Holds Support, Despite Political Backlash
- Stock Splits, Do They Really Impact Investors?
- 3 Tightly-Held Growth Stocks Set Up for Short Squeezes
- Investing in the High PE Growth Stocks
- Science Applications International Is a Wicked Hot Buy in June
Receive News & Ratings for Neoleukin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neoleukin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
